BIOGEN INC. - COMMON STOCK

142,54

10-февраля-25 16:45:00

15 мин. задержка

Акции

+1,19

+0,84%

Сегодняшний диапазон

140,06 - 142,68

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 сен 2024 16:06:38 Источник NetDania Notify
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24 сен 2024 01:00:00 Источник Nasdaq GlobeNewswire
Biogen Board Appoints Two New Independent Directors

12 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

04 сен 2024 07:30:34 Источник Nasdaq GlobeNewswire
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

30 июл 2024 17:15:17 Источник Nasdaq GlobeNewswire
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

30 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26 июл 2024 07:20:38 Источник Nasdaq GlobeNewswire
Biogen Completes Acquisition of Human Immunology Biosciences

02 июл 2024 09:16:51 Источник Nasdaq GlobeNewswire
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

27 июн 2024 19:39:36 Источник Nasdaq GlobeNewswire
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

24 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

09 июн 2024 19:37:43 Источник Nasdaq GlobeNewswire
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

03 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

30 май 2024 16:51:04 Источник Nasdaq GlobeNewswire
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

22 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

16 май 2024 07:30:14 Источник Nasdaq GlobeNewswire
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

14 май 2024 19:33:37 Источник Nasdaq GlobeNewswire
Biogen Reports Progress on Corporate Responsibility Priorities

02 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

25 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

19 апр 2024 09:50:39 Источник NetDania Notify
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

18 апр 2024 09:45:07 Источник NetDania Notify

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.